22-MULTI-47-GS (IMMU-132-11): A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors

Grants and Contracts Details

StatusActive
Effective start/end date7/12/224/27/23

Funding

  • Gilead Sciences Inc: $2.00